封面
市场调查报告书
商品编码
1691770

抗结核病治疗市场 - 全球行业规模、份额、趋势、机会和预测,按疾病类型、按诊断和治疗(诊断、治疗、其他)、按最终用户、按地区和竞争进行细分,2020-2030 年

Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Diagnosis and Treatment (Diagnosis, Treatment, others), By End User, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球抗结核治疗市场价值为 13.205 亿美元,预计在预测期内将出现令人印象深刻的成长,到 2030 年的复合年增长率为 5.90%。抗结核 (TB) 治疗是指用于管理和治疗结核病的药物和治疗策略,结核病是一种主要由结核分枝桿菌引起的细菌感染。结核病是一种传染病,主要影响肺部,但也会影响身体的其他器官和系统。有效的抗结核病治疗对于控制结核病的传播和预防其併发症至关重要。药物敏感型结核病的标准治疗方案通常是每天服用多种第一线药物,持续六至九个月。此持续时间可能因疾病的严重程度和患者对治疗的反应等因素而异。抗药性结核病的治疗更加复杂,可能涉及二线药物。治疗方案可持续 18 至 24 个月或更长时间,使用的特定药物取决于结核病细菌的抗药性模式。接受抗结核病治疗的患者会受到定期监测,以评估其对治疗的反应并发现任何副作用。监测包括临床评估、实验室测试和放射学检查。

市场概况
预测期 2026-2030
2024 年市场规模 13.205亿美元
2030 年市场规模 18.4748亿美元
2025-2030 年复合年增长率 5.90%
成长最快的领域 活动性结核病
最大的市场 北美洲

主要市场驱动因素

抗药性结核菌的出现

主要市场挑战

耻辱和社会决定因素

主要市场趋势

治疗方案简化

目录

第 1 章:产品概述

第 2 章:研究方法

第 3 章:执行摘要

第 4 章:顾客之声

第 5 章:全球抗结核治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依疾病类型(活动性结核病、潜伏性结核病、其他)
    • 依诊断及治疗(诊断(血液检查、影像检查、痰液检查、其他)、治疗(第一线药物、第二线药物、其他)、其他)
    • 按最终使用者(医院、专科诊所、家庭护理等)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第 6 章:亚太地区抗结核治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章:欧洲抗结核治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章:北美抗结核治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 墨西哥
    • 加拿大

第 9 章:南美洲抗结核病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲抗结核病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章:全球抗结核治疗市场:SWOT 分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章: 大环境分析

第 16 章:竞争格局

  • AstraZeneca Plc
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

第 17 章:策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 17353

Global Anti-Tuberculosis Therapeutics Market was valued at USD 1320.50 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.90% through 2030. Anti-tuberculosis (TB) therapeutics refer to the medications and treatment strategies used to manage and cure tuberculosis, a bacterial infection primarily caused by Mycobacterium tuberculosis. TB is a contagious disease that primarily affects the lungs but can also affect other organs and systems in the body. Effective anti-TB therapeutics are essential for controlling the spread of TB and preventing its complications. Standard treatment regimens for drug-susceptible TB typically involve a combination of first-line drugs taken daily for six to nine months. This duration may vary based on factors like the severity of the disease and the patient's response to treatment. Treatment for drug-resistant TB is more complex and may involve second-line drugs. Regimens can last for 18 to 24 months or longer, and the specific drugs used depend on the resistance pattern of the TB bacteria. Patients receiving anti-TB treatment are regularly monitored to assess their response to treatment and to detect any adverse effects. Monitoring includes clinical evaluations, laboratory tests, and radiological examinations.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1320.50 Million
Market Size 2030USD 1847.48 Million
CAGR 2025-20305.90%
Fastest Growing SegmentActive TB
Largest MarketNorth America

Key Market Drivers

Emergence of Drug-Resistant TB Strains

Drug-resistant TB occurs when the bacterium that causes TB, Mycobacterium tuberculosis, becomes resistant to one or more of the drugs commonly used to treat the disease. Multidrug-Resistant TB (MDR-TB) is defined as resistance to both isoniazid and rifampin, which are the two most potent first-line anti-TB drugs. MDR-TB is more challenging to treat than drug-susceptible TB because it requires a longer duration of treatment with second-line drugs, which are less effective and often have more side effects. Extensively Drug-Resistant TB (XDR-TB) is a more severe form of drug resistance and is defined as resistance to isoniazid and rifampin (MDR-TB) plus resistance to any fluoroquinolone and at least one of three injectable second-line drugs (amikacin, kanamycin, or capreomycin). XDR-TB is even more challenging to treat and often requires highly toxic medications with limited efficacy.

One of the primary factors driving drug resistance is the incomplete or inadequate treatment of TB. When patients do not complete the full course of their prescribed TB medications or when the drugs are not administered correctly, it creates conditions that allow the TB bacteria to develop resistance to the drugs. The inappropriate use of antibiotics, including the use of TB drugs for non-TB infections or the use of low-quality or substandard medications, can contribute to drug resistance. Patients may fail to adhere to their TB treatment regimens for various reasons, such as experiencing side effects, stigma associated with TB, or challenges with accessing healthcare services.

Non-adherence can result in treatment failure and drug resistance. Drug-resistant TB strains can be transmitted from person to person. Close contact with an individual infected with a drug-resistant strain can lead to new cases of drug-resistant TB. Poor infection control measures in healthcare settings can facilitate the spread of drug-resistant TB strains, particularly in hospitals and clinics. In some regions, there may be limited access to second-line anti-TB drugs or diagnostic tools to detect drug resistance. This can delay the identification and appropriate treatment of drug-resistant cases. Individuals with compromised immune systems, such as those living with HIV, are at higher risk of developing drug-resistant TB due to their reduced ability to fight off the infection. This factor will help in the development of the Global Anti-Tuberculosis Therapeutics Market.

Key Market Challenges

Stigma and Social Determinants

TB has historically carried a social stigma due to its contagious nature. People with TB may face discrimination and social isolation, which can discourage them from seeking diagnosis and treatment. Individuals diagnosed with TB may internalize societal stigma, leading to feelings of shame and guilt. This self-stigma can negatively affect mental health and willingness to adhere to treatment. Stigma can lead to delays in seeking diagnosis and treatment. Individuals may avoid healthcare facilities out of fear of being stigmatized, leading to delayed diagnosis and worsening of their condition. Stigmatized individuals may be less likely to adhere to their TB treatment regimens, which can lead to treatment failure and the development of drug-resistant TB strains.

Social determinants such as poverty, homelessness, and limited access to healthcare are often linked to a higher risk of TB. Vulnerable populations face increased challenges in accessing diagnosis and treatment, exacerbating the impact of stigma. TB-HIV co-infected individuals often face compounded stigma and discrimination. Managing both diseases require specialized care and support. Reducing TB-related stigma requires education and awareness campaigns that address misconceptions and promote empathy and understanding. These initiatives are essential but require resources and sustained efforts.

Key Market Trends

Treatment Regimen Simplification

Traditional TB treatment regimens often involve multiple pills taken daily for several months. Simplified regimens aim to reduce the number of pills, making it easier for patients to adhere to their treatment plans. Fixed-Dose Combinations (FDCs) combine multiple anti-TB drugs into a single tablet, reducing the complexity of treatment. This approach simplifies dosing schedules and enhances patient adherence. Efforts are underway to develop shorter-duration treatment regimens for TB. For example, some clinical trials have explored the feasibility of shorter treatment courses, such as the 4-month regimen for rifampin-sensitive TB. Simplified regimens may involve fewer clinic visits for drug administration or monitoring. This is particularly important for patients who face challenges in accessing healthcare facilities.

Integrating TB treatment with other healthcare services, such as HIV care, maternal and child health, and non-communicable disease management, can simplify care for patients with multiple health needs. Developing pediatric-friendly formulations of anti-TB drugs, including child-appropriate FDCs and liquid formulations, simplifies treatment for children with TB. Mobile health (mHealth) technologies and digital tools can provide treatment reminders, track medication adherence, and support patients in adhering to their treatment regimens. Community health workers and TB treatment supporters can play a crucial role in simplifying treatment by delivering medications to patients in their communities and providing support. Improved diagnostics, such as molecular tests that rapidly detect TB and drug resistance, contribute to more precise treatment decisions and regimens.

Key Market Players

  • AstraZeneca Plc.
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

Report Scope:

In this report, the Global Anti-Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Tuberculosis Therapeutics Market, By Disease Type:

  • Active TB
  • Latent TB
  • Others

Anti-Tuberculosis Therapeutics Market, By Diagnostic and Treatment:

  • Diagnosis
    • Blood Tests
    • Imaging Tests
    • Sputum Tests
    • Others
  • Treatment
    • First Line of Drug

O Isoniazid

O Ethambutol

O Rifampin

O Others

    • Second Line of Drugs

O Thiacetazone

O Paraaminosalicyclic Acid (PAS)

O Others

    • Others
  • Others

Anti-Tuberculosis Therapeutics Market, By End-User:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Anti-Tuberculosis Therapeutics Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Tuberculosis Therapeutics Market.

Available Customizations:

Global Anti-Tuberculosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Tuberculosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Active TB, Latent TB, Others)
    • 5.2.2. By Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others)
    • 5.2.3. By End User (Hospitals, Specialty Clinics, Homecare, others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Anti-Tuberculosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Diagnosis and Treatment
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Diagnosis and Treatment
        • 6.3.1.2.3. By End User
    • 6.3.2. India Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Diagnosis and Treatment
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Diagnosis and Treatment
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease Type
        • 6.3.4.2.2. By Diagnosis and Treatment
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease Type
        • 6.3.5.2.2. By Diagnosis and Treatment
        • 6.3.5.2.3. By End User

7. Europe Anti-Tuberculosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Diagnosis and Treatment
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Diagnosis and Treatment
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Diagnosis and Treatment
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Diagnosis and Treatment
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Diagnosis and Treatment
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Diagnosis and Treatment
        • 7.3.5.2.3. By End User

8. North America Anti-Tuberculosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Diagnosis and Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Anti-Tuberculosis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Diagnosis and Treatment
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Anti-Tuberculosis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Diagnosis and Treatment
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Anti-Tuberculosis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Diagnosis and Treatment
        • 8.3.3.2.3. By End User

9. South America Anti-Tuberculosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Diagnosis and Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Anti-Tuberculosis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Diagnosis and Treatment
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Anti-Tuberculosis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Diagnosis and Treatment
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Anti-Tuberculosis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Diagnosis and Treatment
        • 9.3.3.2.3. By End User

10. Middle East and Africa Anti-Tuberculosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Diagnosis and Treatment
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Anti-Tuberculosis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Diagnosis and Treatment
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Anti-Tuberculosis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Diagnosis and Treatment
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Anti-Tuberculosis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Diagnosis and Treatment
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Anti-Tuberculosis Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. AstraZeneca Plc
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Johnson & Johnson Private Limited
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Eli Lilly and Company
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. F. Hoffmann-La Roche Ltd.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Mylan N.V.
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Teva Pharmaceutical Industries Ltd.
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Sanofi SA
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Novartis AG
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Sun Pharmaceutical Industries Ltd.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Merck & Co., Inc.
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer